Beta bionics CCO Mark Hopman sells $664,550 in company stock

Beta Bionics, Inc. (NASDAQ: BBNX) saw Chief Commercial Officer Mark Hopman sell 35,994 shares of common stock on September 9, 2026, for a total of $664,550. The shares were sold at $18.46 each, and the stock has since risen to $21.89, representing an 18% gain from Hopman's sale price and a 32% return over the past week. The sale was made in accordance with a Rule 10b5-1 trading plan adopted on June 10, 2026, and corrected an earlier filing with inaccurate share numbers.

Mr. Hopman now holds 88,033 shares of Beta Bionics common stock. Despite the sale, Beta Bionics reported a 38% increase in revenue for Q2 2026, reaching $32 million, but also posted a larger-than-expected loss of 53 cents per share, compared to expectations. The company plans to raise $125 million in a common stock offering and recently received FDA clearance for its Mint disposable patch pump, which is set to be fully commercialized in the U.S. by Q1 2027.

UBS raised its price target for Beta Bionics to $25.00 from $22.00 with a Buy rating, while William Blair initiated coverage with a Market Perform rating, highlighting the AID algorithm on the iLet insulin pump.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.